These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 34952433)
1. Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK). Fu T; Zuo Y; Zhong Z; Chen X; Pan Z Eur J Med Chem; 2022 Feb; 229():114051. PubMed ID: 34952433 [TBL] [Abstract][Full Text] [Related]
2. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines. Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706 [TBL] [Abstract][Full Text] [Related]
3. Discovery of 2,5-diaminopyrimidine derivatives as the first series of selective monomeric degraders of B-lymphoid tyrosine kinase. Fu T; Zuo Y; Xue G; Zhou D; Pan Z Eur J Med Chem; 2023 Aug; 256():115460. PubMed ID: 37163946 [TBL] [Abstract][Full Text] [Related]
4. Discovery of promising B lymphocyte kinase inhibitors using structure-guided virtual screening. Yang S; Wahab S; Almoyad MAA; Chen Y; Kalam N; Khalid M J Biomol Struct Dyn; 2024 Aug; 42(13):7054-7064. PubMed ID: 37688373 [TBL] [Abstract][Full Text] [Related]
5. Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine. Kwarcinski FE; Fox CC; Steffey ME; Soellner MB ACS Chem Biol; 2012 Nov; 7(11):1910-7. PubMed ID: 22928736 [TBL] [Abstract][Full Text] [Related]
6. Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors. Francini CM; Musumeci F; Fallacara AL; Botta L; Molinari A; Artusi R; Mennuni L; Angelucci A; Schenone S Molecules; 2018 Sep; 23(9):. PubMed ID: 30227617 [TBL] [Abstract][Full Text] [Related]
7. Dysfunctional BLK in common variable immunodeficiency perturbs B-cell proliferation and ability to elicit antigen-specific CD4+ T-cell help. Compeer EB; Janssen W; van Royen-Kerkhof A; van Gijn M; van Montfrans JM; Boes M Oncotarget; 2015 May; 6(13):10759-71. PubMed ID: 25926555 [TBL] [Abstract][Full Text] [Related]
8. Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening. Lin LG; Xie H; Li HL; Tong LJ; Tang CP; Ke CQ; Liu QF; Lin LP; Geng MY; Jiang H; Zhao WM; Ding J; Ye Y J Med Chem; 2008 Aug; 51(15):4419-29. PubMed ID: 18610999 [TBL] [Abstract][Full Text] [Related]
9. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma. Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826 [TBL] [Abstract][Full Text] [Related]
10. 'Piperazining' the catalytic gatekeepers: unraveling the pan-inhibition of SRC kinases; LYN, FYN and BLK by masitinib. Aljoundi AK; Agoni C; Olotu FA; Soliman ME Future Med Chem; 2019 Sep; 11(18):2365-2380. PubMed ID: 31516031 [No Abstract] [Full Text] [Related]
11. Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases. Lin J; Shen W; Xue J; Sun J; Zhang X; Zhang C Eur J Med Chem; 2012 Sep; 55():39-48. PubMed ID: 22818848 [TBL] [Abstract][Full Text] [Related]
12. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src. Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839 [TBL] [Abstract][Full Text] [Related]
13. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase. Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525 [TBL] [Abstract][Full Text] [Related]
14. GRID and docking analyses reveal a molecular basis for flavonoid inhibition of Src family kinase activity. Wright B; Watson KA; McGuffin LJ; Lovegrove JA; Gibbins JM J Nutr Biochem; 2015 Nov; 26(11):1156-65. PubMed ID: 26140983 [TBL] [Abstract][Full Text] [Related]
15. Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors. Francini CM; Fallacara AL; Artusi R; Mennuni L; Calgani A; Angelucci A; Schenone S; Botta M ChemMedChem; 2015 Dec; 10(12):2027-41. PubMed ID: 26514807 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment. Cui Z; Chen S; Wang Y; Gao C; Chen Y; Tan C; Jiang Y Eur J Med Chem; 2017 Aug; 136():372-381. PubMed ID: 28525838 [TBL] [Abstract][Full Text] [Related]
17. Substrate activity screening with kinases: discovery of small-molecule substrate-competitive c-Src inhibitors. Breen ME; Steffey ME; Lachacz EJ; Kwarcinski FE; Fox CC; Soellner MB Angew Chem Int Ed Engl; 2014 Jul; 53(27):7010-3. PubMed ID: 24797781 [TBL] [Abstract][Full Text] [Related]
18. ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases. Nam NH; Lee S; Ye G; Sun G; Parang K Bioorg Med Chem; 2004 Nov; 12(22):5753-66. PubMed ID: 15498652 [TBL] [Abstract][Full Text] [Related]
19. Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine. Du G; Rao S; Gurbani D; Henning NJ; Jiang J; Che J; Yang A; Ficarro SB; Marto JA; Aguirre AJ; Sorger PK; Westover KD; Zhang T; Gray NS J Med Chem; 2020 Feb; 63(4):1624-1641. PubMed ID: 31935084 [TBL] [Abstract][Full Text] [Related]